www.fdanews.com/articles/82723-pozen-receives-approval-for-mt-100-in-the-united-kingdom
POZEN RECEIVES APPROVAL FOR MT 100 IN THE UNITED KINGDOM
November 29, 2005
Pozen, Inc., a pharmaceutical company focused primarily on products for the treatment of acute and chronic pain, migraine and other pain-related conditions, announced today the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a Marketing Authorization for MT 100 for the acute treatment of migraine. MT 100 was developed as an oral, first-line treatment for migraine.
Doctor's Guide (http://www.docguide.com/news/content.nsf/news/8525697700573E18852570C70057429E)